NCT02713997View on ClinicalTrials.gov

Anti-inflammatory Therapy to Improve Outcomes After TPIAT

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

July 1, 2023

Study Completion Date

May 1, 2025

Conditions
Pancreatitis, Chronic; Diabetes; Transplant
Interventions
DRUG

etanercept

50 mg on day 0 SQ; 25 mg subcutaneous (SQ) on days 3, 7, 10, 14, and 21 relative to TPIAT

DRUG

Alpha 1-Antitrypsin

90 mg/kg intravenous infusion on days -1, and +3, 7, 14, 21, and 28 post-transplant

Trial Locations (1)

55455

University of Minnesota, Minneapolis

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Minnesota

OTHER

NCT02713997 - Anti-inflammatory Therapy to Improve Outcomes After TPIAT | Biotech Hunter | Biotech Hunter